Aktuellt
SENASTE
Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new subcutaneous version of the main candidate BI-1206, which should be free of some of the side effects of the intravenous version.
LÄS MER
